Event in Progress:
Discover the latest content that has just been published on Research Tree
Ebro Foods made a significant impression with its 9-month results. The company’s recent investments are starting to pay off. In general, inflation costs are starting to decrease, positively affecting margins. Besides the very strong 9M 2023 figures reported by the company, *we are even more encourged by the company’s announcement regarding the development of its value-added strategy.
Companies: Ebro Foods (EBRO:BME)Ebro Foods SA (EBRO:MCE)
AlphaValue
Ebro Foods posted a strong H1, primarily led by the rice division. The implementation of its value-added products strategy is well underway and is expected to have a greater impact on upcoming results. These H1 results once again confirmed that the company is a natural hedge against the decline in consumer purchasing power.
In the Q1-2023, Ebro Foods once again demonstrated its resilience in the face of the current macroeconomic environment. The company’s topline was largely bolstered by its rice business, which has proven resistant to the challenges of drought and flooding. Despite a somewhat tempered outlook, Ebro remains confident in its ability to deliver a robust year.
Ebro did slightly better than the guidance given three months ago. The year was clearly driven by the first half, the third and fourth quarters having encountered many challenges which are expected to continue in FY23. Despite this, it can be said that Ebro does not feel too bad about the situation.
Ebro had held up well up to this point but we were not that surprised to see a relatively poor Q3. The group is facing a lot of pressures that are likely to continue in the coming months.
Easy comps have driven up the H1 results, but the environment remains tight and Ebro expects lower H2 demand which should in the end not help the rest of the year.
A strong performance in Q1 (better-than-expected) is welcomed given the more cautious tone of the company for the following months.
9m FY21 figures were obviously down vs. FY20 (strong negative comps), but they were still remarkable compared with FY19. We expected very complicated management of inflation for the group, but we see a rather good surprise on that side. On the other hand, we should be more cautious about 2022, when the current hedging will roll off.
Unsurprisingly, we see a decrease in the results compared to 2020, but still good progress compared to 2019, which confirms the good trajectory of the group.
With no surprise, Q1 FY21 top and bottom lines declined due to tough comps. The momentum remains, however, strong looking at CAGR 21/19, but input cost inflation is now the main threat looking forward.
Unsurprising very strong FY20 results (but still even more than our expectations). We believe Ebro is at a turning point and we continue to be positive on the stock.
Although the figures showed greater volatility, the rise in demand triggered by the COVID-19 pandemic continues to dominate Ebro’s results. Deleveraging is well on track.
Companies: Ebro Foods SA
After a strong set of FY19 figures, Ebro’s Q1 benefited from COVID-19 due to increasing rice and pasta consumption. Q2 should be even better, while we expect a gradual return to normal starting in Q3. EBITDA is affected by raw material prices increase, but the group is confident that the FY20 bottom line should be better yoy.
A strong set of FY19 figures, especially thanks to strong comparables. We note that organic investments had begun to bear fruit, although the company doesn’t expect to see the relevant impacts until 2021. In the mean time, it is actually debt that is going up.
The group reported a strong set of Q3 FY19 results, beating analysts’ expectations on the bottom line. Ebro’s investments finally pushed up growth… as well as the group’s debt.
Research Tree provides access to ongoing research coverage, media content and regulatory news on Ebro Foods SA. We currently have 54 research reports from 2 professional analysts.
Companies: Premier Foods plc
Shore Capital
Companies: Genus plc
Liberum
The second full year of Greggs’ five-year growth plan to double revenue by FY26 should be marked down as very successful, especially so given the challenging external environment. Unlike many consumer-facing companies, high selling price inflation was accompanied by volume growth, leading to good market share gains. The consumer is responding well to new initiatives to grow revenue in new dayparts and digital channels. Profitability was well-managed with better recovery of input cost inflation t
Companies: Greggs plc
Edison
Carr’s Group has announced an updated strategy that offers the potential for value realisation and creation from a number of avenues. These include: value realisation of the Engineering Division; the ability to significantly reduce central costs; and longer-term value creation in the Agriculture Division as a focused business with recovery potential and a strategy to leverage its strong market positions for growth.
Companies: Carr's Group PLC
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (
Companies: TXG NDVA TSVT BCOW Z29 TXG NCYT GNS SUN AMS OMG APH EKF EAH IMM AGL DEMG AGY TSTL IPO GDR ETX TRX HVO CTEC AVO OXB DEST VLG IXI VAL INDV AGR AVCT BAI 123F IMCR BCOW
Hardman & Co
We are reiterating our Buy rating, projections and $22.50 price target for Betterware de Mexico with the company announcing 1Q24 (March) results after the close on Thursday. We believe, with momentum returning at the Betterware division, JAFRA remaining on a new product and marketing focus, the United States market becoming a larger emphasis and BWMX continuing to offer a compelling (and secure) dividend yield of 8.5%, BWMX remains well positioned to reward investors on multiple levels, and we r
Companies: NUS MED NUS BWMX MED DDMX
Small Cap Consumer Research LLC
We are reiterating our Buy rating, $22.50 price target and projections for Betterware de Mexico after reviewing the March catalog. March completed a 1Q with material YoY positives, from higher SKU counts, rising cadence of new and debuting products, a return of key favorites and continued reductions in overall discounting levels. We believe Betterware management has been able to capitalize on the return to normalcy for their supply chain to roll out compelling new items, offer normalized pricing
Greggs (GRG) enjoyed a stronger-than-expected end to FY23 with sales ahead of our estimates and consensus forecasts, enabling GRG to meet its profit expectations for the year. GRG’s strong revenue growth and an improved profit performance in FY23 means it has fared better than many other consumer-facing names during the year. With lower inflationary pressures, the company enters FY24 in a better place with respect to its selling price versus cost inflation than at the start of FY23, when it was
11 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object
Companies: NICL DELT COG ABDP PYC W7L WSBN KIBO CRTA
Hybridan
Companies: TXP CRPR SNX ARBB TON FA/ SBRY MTW BWNG HFG HUW UJO MOTR OBD NRR DEST CBOX SDX EYE FDM EPWN SAVE W7L ACRL FAR BVC MWE MATD SENX
Companies: Anpario plc
Companies: OHT TIDE ELCO TSTL VEL BBSN
Cavendish
Companies: OHT PCIP SND CORA
Share: